Biogen ups outlook as new MS drug tops forecasts Biogen Idec today reported a higher first-quarter profit as sales of its new Tecfidera multiple sclerosis drug extended a run of eclipsing Wall Street sales expectations. Business • 23 Apr 14
Biogen ups outlook as new MS drug tops forecasts Biogen Idec today reported a higher first-quarter profit as sales of its new Tecfidera multiple sclerosis drug extended a run of eclipsing Wall Street sales expectations. Business • 23 Apr 14
Biogen's first quarter profits beat estimates Biogen Idec today reported higher-than-expected first quarter profit, helped by low taxes and sales growth of its injectable MS treatments. Business • 25 Apr 13
Biogen's first quarter profits beat estimates Biogen Idec today reported higher-than-expected first quarter profit, helped by low taxes and sales growth of its injectable MS treatments. Business • 25 Apr 13
